SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

ORIC Pharmaceuticals, Inc. (ORIC) News

Follow ORIC Pharmaceuticals, Inc. (ORIC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol ORIC Asset equity Sector Markets 90 days 10 Last 7.71 Updated Nov 18, 2026, 08:01 AM UTC Open live news feed Open ORIC chart & news
M ORIC Posts $0.44 Loss; Citi Raises Target, BTIG Keeps Buy EQUITY | Nov 18, 2026, 08:01 AM UTC M Oric Reports Enozertinib Phase 1b Results, Plans Phase 3 in 2027 Oric reported systemic and intracranial activity for enozertinib in Phase 1b and plans a global Phase 3 trial in the first half of 2027. EARNINGS | Oct 23, 2026, 12:03 PM UTC L Oric Pharmaceuticals Initiated at Buy by BTIG Ratings actions from Benzinga NEWS | Sep 23, 2026, 10:46 AM UTC L BTIG initiates coverage of ORIC Pharmaceuticals with Buy rating, $26 price target BTIG initiated coverage on ORIC Pharmaceuticals's stock with a rating of Buy and a price target of $26.00.The price target implies an upside of 92.6% from the Sep 22 close of $13.50.Key takeaways from the analyst noteStr EQUITY | Sep 23, 2026, 10:36 AM UTC L ORIC: Advancing late-stage cancer programs with strong safety profiles and robust funding through 2028 The company is advancing two late-stage oncology programs: rinzimetostat for prostate cancer, with a phase III trial underway and strong safety differentiation, and enozertinib for lung cancer, targeting brain metastases NEWS | Sep 15, 2026, 03:24 PM UTC L ORIC: Advancing late-stage cancer programs with strong safety differentiation and robust financial runway The company is advancing two late-stage oncology programs: rinzimetostat for prostate cancer, now in Phase III, and enozertinib for lung cancer, with a key data update expected soon. Differentiation is driven by safety a NEWS | Sep 15, 2026, 02:56 PM UTC L ORIC: Late-stage cancer programs advance with strong funding, key data, and safety differentiation ahead Two late-stage oncology programs are advancing, with rinzimetastat in phase III for prostate cancer and enozertinib targeting lung cancer. Key differentiators include safety and potential resistance advantages, with majo EQUITY | Sep 09, 2026, 07:51 PM UTC L ORIC: Advancing late-stage cancer therapies with strong efficacy, safety, and major market potential Two late-stage oncology programs, rinzimetostat and enozertinib, are advancing through pivotal trials targeting high unmet needs in prostate cancer and NSCLC, respectively. Both show strong efficacy, safety, and blockbus EQUITY | Sep 09, 2026, 12:49 PM UTC L ORIC - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) EQUITY | Sep 04, 2026, 08:30 PM UTC L ORIC - ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences ORIC - ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences EQUITY | Sep 02, 2026, 08:05 PM UTC L ORIC - ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates ORIC - ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates EARNINGS | Aug 03, 2026, 08:07 PM UTC L ORIC oric® Pharmaceuticals announces initiation of himalayas-1 phase 3 trial in mcrpc evaluating rinzimetostat in combination with nubeqa® ( ORIC oric® Pharmaceuticals announces initiation of himalayas-1 phase 3 trial in mcrpc evaluating rinzimetostat in combination with nubeqa® (darolutamide), supported by clinical collaboration with Bayer EQUITY | Jul 14, 2026, 08:05 PM UTC